{"name":"Allay Therapeutics, Inc.","slug":"allay-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Allay Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for pain management. The company's lead product, bupivacaine hydrochloride without epinephrine, has been discontinued, indicating a shift in its pipeline strategy.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOdUlsbS1adThlZUxIZzl5ekNDQlNtZEpfSXBUbFZWLVhKR1ZYdHdEVllrLTdEOWJGMXFZVVdPQkhfNWhzQzdLX2J3SldESlpVX2xpUmNVWjRhWkpPUkVkbjBpcDhFQ2lwaUo2S3gwU2NLR1lrQmFlbDFld1o4bVRpQnR0UWhMQU1GRGJ6R0RZNnRGcnVfdDBocGNjc00?oc=5","date":"2026-03-27","type":"pipeline","source":"openPR.com","summary":"Knee Surgeries And Arthroplasty Pain Management Therapeutics - openPR.com","headline":"Knee Surgeries And Arthroplasty Pain Management Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSjJzWEhjNENoSy1kbXIxTWF4ak9WRWpOUW5FR2NIbnRyamJ0ZDVfS3NyZ3BrdHVTeU9sLVdhWUtVVU1tQXZENW9OLXNEZTdMWVR3U0NoX09MaWExQWhvZ003U0R3VnNYcVZPZGhUNlE5OHd4NG5GaGhCM0wwVGtVclY1QUF6a2RvZHJKUlpWTkNrWWN3M19aMndQc1UzWlpjZ2YxLVgyalg1Zlo4Zzlyd3hEeHVQSk85ZzJpNExqNHlKckZmNXhPVUJxNUhTcTRJWW5yNGw4d1dRVUtrS1hGMUdFcjhWZDZFYVVv?oc=5","date":"2026-01-13","type":"pipeline","source":"PR Newswire","summary":"Tulavi Therapeutics Receives Innovative Technology Contract from Vizient for the allay™ Hydrogel Cap - PR Newswire","headline":"Tulavi Therapeutics Receives Innovative Technology Contract from Vizient for the allay™ Hydrogel Cap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPdm1LczFlN25RMzEzYkJGUWsyM1poMHFVcHM0VmFuQ0NKdU9rRzk1SXUxR0t1V3piZVBmaXBOSHpHTEtyeE1iN1lHWGpaUy1ISUlYMHNjUWM5eVFHQ2VZTzRVV1hMb1pjSHhrcHZPWXZWZkxzQXlrUFlGclkwdlZaUk96V3liRFk?oc=5","date":"2025-12-11","type":"pipeline","source":"Yahoo Finance","summary":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance","headline":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Al","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOUmQybk9TX2VZZTFLQVZuek1GNl9ZdUU2eFlSZTdVTWpqZEtLU3M2MnRVLURYT0VfWVFBMk95YTZEOHF0ZHhDZmFIcU0yWHBQUWY3TTQybWFVWmUyMkNBdlNGZ3l0TzhOSUJwZklSd0VONXFLd3RTSER4dDV5T1lkeUNrYnM4NTZzb1ZzVUFualNPV25vSXRIaXU4U2l4YjVkQUlQeE5MeWtpd3FqaHk4TVJwVWYyRS0yb0piNU9vZ2ZFUG1zdTJCWEdYbG1nQW1PNW9CWF9fWkEyY1Nwek9IenlzcERnTk96SzNxOWdvSDVGeUFXOXdZRFRrcndESU01SkNPMVN3X1pmQnQ5V1A1WllCaUhrRzJLSHVTdTY0cF80QQ?oc=5","date":"2025-09-24","type":"trial","source":"PR Newswire","summary":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPRVktd1hLd0pkOGdndGJPNXpndm1XTk5Vb3dxT1ZvZDlhU1h4NDJrNHNsaHNIRUhSbU9oNEVwM2NRRWhBbUVORXg2WGthSkVjV3EzMzR6VEVUSzQ4OTJqTllaV3JSeWNRQU1NM1ZqMFZvcW5NRmFIRzg2S0ZSdGlGZmVhYmhqalZaSm5QT3FybU9JbUx0WmlTVjJYMWpYd1ltNXVncDBoRkdiQzhiVVh4ZEtmVXNjODJHYjQxd0VZdw?oc=5","date":"2025-06-20","type":"pipeline","source":"MedCity News","summary":"Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs - MedCity News","headline":"Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNNHdBdDRkeExlOS1NWm1hTklfUExDbmRfRmVRMHA5Sk1TamVSeE9EQ2dDYlNhOWRUVFhSZDhXNFVlX0Z1VjROUXFGTGZGWlJHenlSTlRLX3F5RTZwemxwZnlnVjdvYVdaMjdZYnk5VmFmWkRBZ3Z3SnZDb04wN2lNUmJEb24yQTFITjNPQnpRZ3BVaV9HSzZCV0pBWFp5TTA?oc=5","date":"2025-06-10","type":"pipeline","source":"BioWorld News","summary":"Allay’s $57.5M extends postsurgical pain relief with ATX-101 - BioWorld News","headline":"Allay’s $57.5M extends postsurgical pain relief with ATX-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOY1dYdHVrRE9ZWUlWeEhnM2pJRmpqVEg2VWJ0U1VXRjVTYVA1dnlQZ3NfdVVjTW1xS01fQ0VBSWs1dk12QkliYmtpUXdoQ1ZBZ281b0JyaW1fM0Q0Q3QxVWVQS2ViMFA4UkM0WmNfVklJVnRPRmtVUDF1SEV0U0swQUhyR216dEFJX3lsU3BGalRpQUFNRDBLNDZTRS1jMlByNGs1Y2lNdl80YTNZTFR5S0JKblZIajJhaGdIeUsyOEpEUWR3N2NaZHhPbDMyLWJfUUl6bU4zN0lzaEpsb2dCR201dWs3b2NFVkE?oc=5","date":"2025-06-06","type":"regulatory","source":"The Business Times","summary":"Lightstone Ventures, Temasek's ClavystBio co-lead Allay Therapeutics' US$57.5 million Series D funding - The Business Times","headline":"Lightstone Ventures, Temasek's ClavystBio co-lead Allay Therapeutics' US$57.5 million Series D funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxOb3NCU2wzVVFOWnJIYVVxMTVCT19CZzZHcnMxUzR0RHQzaEh1UFA3YlZmR1h2SDlrZTQzb1NRRnEySm9yODZWTVhIWmFLV3pxbU0yUElISko5MmF3Z0F1NjYyQUlKWEluVGdYS2ZHYV85dmlQS0NGSlBFVENBcUZHQmlkRVc2WEpOeHNESEpORXZnLTByWmdJQTNueVpGTTFWVmlCdEM0Y194cC1zTUF1RzZQQVIwNnEyMnR3NVljdjEtUDJlWEZfTThRMTB1RmZoTXd2NV92VXRkWnNYbWVhY29keGgydzdxcnJpUzBrb2g5T3dXZ3l0N3dlMHJYZUN1NjR0aEZwblQ4MHBjYlNrSjhuYjZ2ZFhpcFJMR0lzQ09VbEd5WENUd2NfTkF6bkNSVGlfWTY1VFREZlF3QmFYeGt3TERoNUtS?oc=5","date":"2025-06-05","type":"pipeline","source":"Business Wire","summary":"Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management - Business Wire","headline":"Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxPRl9qeDd2dEI4Tk5Ga1hVY3lydHNmSDdKNDBzUUEyWXNkSFJpWEFpaTlyRldTaFNwTGxENW5fQV9ZcHdWZHRZeWJyaFlKYjI0bkpwYjZVcDQzeWVfMzd1dTJIbkFsazlqOW1KOWVNcmJHeEpqa0NqcFVORGpKZWFYN0o4YWZaNmE1NFk4QkZjVC04NHRBd0VGUEc1b3ZNVEE0SVl6QlZNTjg0Zk9Uc2lnY0dZMlhNZVBxbkR2Q08tbXpHZ0hLTUhKNlNoMFU4djBxR3RaTmdYZFlLTGYweWtSSVUtTXJ1eU52b0RLYUt2T3gyNm1GbnNtbnIzcGtpTkhtcUtEbVBJcF9oSFktVWllZzVGUEUxTkkyZGJzbzJUV0Rib2lZQVEwZUEta1dDSjZMNWc1ZXJHZDQ?oc=5","date":"2024-10-24","type":"pipeline","source":"Business Wire","summary":"Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management - Business Wire","headline":"Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNWEMtaGJfSmhsZ2wwMkFaTms2QlY4bnNZNVY4YlQxazZPb2RPODlKd0RBSkNtdDVmQnQ3dTZjd01CaVZHWDBlTW9DM19DYXl6dUdQVWRSdFlPWDB2WG5mQzAxRE1IdE8zdWc0UkFPOUdNVUtYSHZXZWxDdnNhcHJtUmdZQlVIM3hy?oc=5","date":"2023-05-29","type":"pipeline","source":"OpenSecrets","summary":"Pharmaceuticals/Health Products Lobbying Profile - OpenSecrets","headline":"Pharmaceuticals/Health Products Lobbying Profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNeVN5b0liN28wcXdTdzEyNjZ6NWpQelR1dURjeVJCQ2s0WjZkWGpwdUtmb3hKRFZ5OExsNGItaFVNRi1lcFpzMTFFZHJRN1dCX0o3R0w3bkFvdU90cWprOUpQS0FuU1EtTi0xWGxfUWlFaDI5a3c2WVplbHpsRkUtVk5XcmIyaU96SEJZYTNtbVo?oc=5","date":"2023-04-10","type":"regulatory","source":"Timmerman Report","summary":"In Support of FDA’s Authority to Regulate Medicines - Timmerman Report","headline":"In Support of FDA’s Authority to Regulate Medicines","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}